| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CSII | Common Stock | Purchase | $46.3K | +2.5K | +0.44% | $18.52 | 572K | Feb 7, 2022 | Direct | F1 |
| transaction | CSII | Common Stock | Award | $0 | +5.48K | +0.96% | $0.00 | 578K | Feb 8, 2022 | Direct | F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | CSII | Restricted Stock Units | 34.3K | Feb 7, 2022 | Common Stock | 34.3K | Direct | F3 |
| Id | Content |
|---|---|
| F1 | The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $18.50 to $18.58 inclusive. The reporting person undertakes to provide Cardiovascular Systems, Inc., any security holder of Cardiovascular Systems, Inc., or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
| F2 | Restrictions lapse as to 2,739 shares on 2/12/23 and as to 2,738 shares on 2/12/24. |
| F3 | Each restricted stock unit represents the right to receive a payment from the Company equal in value to the market price per share of the Company's common stock on the date of payment and shall be payable in cash or shares of Company common stock beginning six months following the termination of the reporting person's board membership. |